000			02156 a2200565 4500
005			20250516005627.0
264		0	_c20111003
008			201110s 0 0 eng d
022			_a1432-0843
024	7		_a10.1007/s00280-010-1486-7 _2doi
040			_aNLM _beng _cNLM
100	1		_aPeirce, Susan K
245	0	0	_aThe PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. _h[electronic resource]
260			_bCancer chemotherapy and pharmacology _cAug 2011
300			_a325-35 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xantagonists & inhibitors
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Movement _xdrug effects
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aChromones _xantagonists & inhibitors
650	0	4	_aEnzyme Inhibitors _xpharmacology
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInhibitor of Apoptosis Proteins _xmetabolism
650	0	4	_aMice
650	0	4	_aMice, Nude
650	0	4	_aNeuroblastoma _xdrug therapy
650	0	4	_aOligopeptides _xantagonists & inhibitors
650	0	4	_aPhosphoinositide-3 Kinase Inhibitors
650	0	4	_aPhosphorylation _xdrug effects
650	0	4	_aProdrugs _xpharmacology
650	0	4	_aProtein Processing, Post-Translational _xdrug effects
650	0	4	_aProto-Oncogene Proteins c-akt _xmetabolism
650	0	4	_aProto-Oncogene Proteins c-mdm2 _xmetabolism
650	0	4	_aRandom Allocation
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSurvivin
650	0	4	_aTumor Burden _xdrug effects
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aFindley, Harry W
700	1		_aPrince, Chengyu
700	1		_aDasgupta, Anindya
700	1		_aCooper, Todd
700	1		_aDurden, Donald L
773	0		_tCancer chemotherapy and pharmacology _gvol. 68 _gno. 2 _gp. 325-35
856	4	0	_uhttps://doi.org/10.1007/s00280-010-1486-7 _zAvailable from publisher's website
999			_c20273938 _d20273938